LITHIUM CARBONATE Drug Patent Profile
✉ Email this page to a colleague
When do Lithium Carbonate patents expire, and when can generic versions of Lithium Carbonate launch?
Lithium Carbonate is a drug marketed by Able, Alembic Ltd, Apotex Inc, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Hikma, Pharmobedient, Usl Pharma, Watson Labs, Alembic, Glenmark Pharms, Heritage Pharma, Hikma Intl Pharms, Unique, Pfizer, and Sun Pharm Inds Inc. and is included in twenty-nine NDAs.
The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lithium Carbonate
A generic version of LITHIUM CARBONATE was approved as lithium carbonate by HIKMA on January 29th, 1982.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LITHIUM CARBONATE?
- What are the global sales for LITHIUM CARBONATE?
- What is Average Wholesale Price for LITHIUM CARBONATE?
Summary for LITHIUM CARBONATE
| US Patents: | 0 |
| Applicants: | 16 |
| NDAs: | 29 |
| Finished Product Suppliers / Packagers: | 20 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 105 |
| Patent Applications: | 3,960 |
| Drug Prices: | Drug price information for LITHIUM CARBONATE |
| What excipients (inactive ingredients) are in LITHIUM CARBONATE? | LITHIUM CARBONATE excipients list |
| DailyMed Link: | LITHIUM CARBONATE at DailyMed |
Recent Clinical Trials for LITHIUM CARBONATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Centre Hospitalier Universitaire Dijon | PHASE1 |
| Alzamend Neuro, Inc. | PHASE1 |
| Massachusetts General Hospital | PHASE1 |
Pharmacology for LITHIUM CARBONATE
| Drug Class | Mood Stabilizer |
Medical Subject Heading (MeSH) Categories for LITHIUM CARBONATE
Anatomical Therapeutic Chemical (ATC) Classes for LITHIUM CARBONATE
US Patents and Regulatory Information for LITHIUM CARBONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma Intl Pharms | LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 076490-001 | Jun 17, 2003 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Heritage Pharma | LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 205532-001 | Sep 29, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Pharmobedient | LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 202288-001 | Jun 29, 2012 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Heritage Pharma | LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 076366-001 | Aug 21, 2003 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Able | LITHIUM CARBONATE | lithium carbonate | CAPSULE;ORAL | 076823-001 | Jun 29, 2004 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Financial Trajectory for Lithium Carbonate
More… ↓



